NATiAS (Chuo-ku, Kobe), a CDMO (Contract Development and Manufacturing Organization) for oligonucleotide APIs in which Mitsui Chemicals, Toray Engineering, and other companies have invested, is developing a large-scale CDMO using a proprietary manufacturing method that is suitable for mass production and the company will begin to aim new projects…read more

NATiAS, a company that supports the creation of oligonucleotide therapeutics with its novel synthesis technology…read more

NATiAS establishes original mass production technology for oligonucleotide APIs. …read more